Background Warfarin, despite its known limitations, is the reference standard treatment for
patients with AF and risk factors for stroke. We performed a meta-analysis of phase III trials …

Background: It is unclear whether the non–vitamin K antagonist oral anticoagulant agents
rivaroxaban and dabigatran are superior to warfarin for efficacy and safety outcomes in …

Background—Novel oral anticoagulants (NOACs) have been proposed as alternatives to
vitamin K antagonists for the prevention of stroke and systemic embolism in patients with …

Background: Current guidelines recommend using direct oral anticoagulants (DOACs) over
warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to …

Abstract Introduction Novel oral anticoagulants (NOACs) expanded the options for stroke
prevention in atrial fibrillation (AF). Earlier studies comparing their relative effectiveness and …

Aims The aim of this study was to compare the risk of stroke or systemic embolism (SE) and
major bleeding in patients with atrial fibrillation (AF) using dabigatran, rivaroxaban, and …

Aims The introduction of direct oral anticoagulants (DOACs) has broadened the treatment
arsenal for nonvalvular atrial fibrillation, but observational studies on the benefit–risk …

Background The aim of the study was to compare the real-world effectiveness and safety in
atrial fibrillation (AF) patients treated with edoxaban versus other oral anticoagulants …

Anticoagulation is the most-important intervention to prevent stroke in patients with atrial
fibrillation (AF). Despite a lower point prevalence of AF in Asian communities and Asian …

Aims Polypharmacy is prevalent among non-valvular atrial fibrillation (NVAF) patients and
presents a potential issue for the effective management of NVAF. This study compared the …